



## Contexte

Cytomegalovirus (CMV) infection is a major complication of transplantation in hematopoietic stem cell (HSC) recipients. Among the new therapies available, letermovir (LMV) has an interesting safety profile. The currently available oral forms of LMV (PREVYMIS®, 240 and 480mg tablets) are not suitable for pediatric use.

## -> Validate a Stability-indicating assay method, develop an oral liquid form (OLF) of LMV suitable for pediatrics and evaluate its physico-chemical stability,



## Conclusion

This OLF of letermovir responds to a real need in pediatric HSC recipient patients. The use of InOrpha® avoids exposure to excipients with notable effects and its low osmolarity (≈ 180 mOsm/kg) is compatible with a fragile gastrointestinal tract. The assay method is accurate and reproducible according to GERPAC recommendations.

## GERPAC 24èmes journées, Hyères 06 – 08 octobre 2021